
 | "·õ»³Ë¡"MCT¤ò»Ü¹Ô¤·¤¿Ä¾·Â12cm¤ÎµðÂçÃÀ´ÉºÙ˦´â¤Î¼£Îŷи³ ¢¡ | ´ÎÆâÃÀ´É´â ¾ |
 |
 | 1 °À¿À·Ðç±¼ð¤ËÂФ¹¤ë²¹Ç®¼£ÎŤˤè¤ëË̵þ¤Ø¤Î°åÎűç½õ | 22²ó¡¡Âç²ñ |
 |
 | 10ǯ°Ê¾åÀ¸Â¸¤·¤¿´ÎºÙ˦´â¤Î5Îã¡¡¡¦¡¦¡¦¾ÉÎã¤ÎÆâÌõ¤È¼£ÎÅË¡¡¡£¶£¸ºÐ½÷À..35ºÐÃËÀ..
¾ÉÎãÁí³ç¡¦¡¦ ¢¡ | ´Î¡´â ¾ |
 |
 | 12ǯ´Ö¤Î·Ð²áÃæ¤ËExemestane¤¬Ãø¸ú¤·¤¿Æý´â¹üž°Ü¤Î1Îã ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | 13ºÐ½÷À¤Ëȯ¾É¤·¤¿²£Ìæ¶ÚÆù¼ð¤Î1Îã¡¡¡¦¡¦¡¦Æý˼¸¶È¯²£Ìæ¶ÚÆù¼ð¾É¡¦¡¦ ¢¡ | 8·îÂè2½µ(5Æü¡Ë ¾ |
 |
 | 18ǯ´Ö¤Ë7²ó¤ÎŦ½Ð½Ñ¤ò¹Ô¤Ã¤¿¸åÊ¢Ëì»éËÃÆù¼ð¤Î1Îã ¢¡ | £³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾ |
 |
 | 1aaaaa¥Æ¥¹¥È¥Ç¡¼¥¿¤Ç¤¹¡¡¡¦¡¦¡¦¤¢
¤¤
¤¦
¤¨
¤ª
²Á³Ê¥¼¥í±ß¤Ç¡¡¡Ö¹ØÆþ¥Ü¥¿¥ó¡×¤¬½Ð¤Ê¤¤¤è¤¦¤Ë¡¦¡¦ ¢¡ | test ¾ |
 |
 | 2²ó¤Î¼«²ÈËö¾¿·ì´´ºÙ˦°Ü¿¢¸å¤â´²²ò¤òÆÀ¤é¤ì¤º,QOL½Å»ë¤ÎÊý¿Ë¤ÇĹ´ü´Ö´Ñ»¡¤·¤¨¤¿¿À·Ð²ê¼ð¤Î1Îã ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | 2²ó¤Î¼«²ÈËö¾¿·ì´´ºÙ˦°Ü¿¢Ê»ÍÑĶÂçÎ̲½³ØÎÅË¡¤Ë¤è¤ëµßºÑÎÅË¡¤ò¹Ô¤Ã¤¿Æñ¼£À½Ä³ÖÀº¾åÈé¼ð¤Î1Îã | 33-06 |
 |
 | 2ǯÀ¸Â¸¤òÆÀ¤¿GemcitabineÅêÍ¿ÀÚ½üÉÔǽ¿Ê¹Ôç¹´â¤Î2Îã ¢¡ | ç¹Â¡´â ¾ |
 |
 | 3¼ïÎà¤Î´ÁÊýÌô¤Ë¤è¤ê·«¤êÊÖ¤µ¤ì¤¿ÌôʪÀ´Î¾ã³²¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | 4·¿¥¹¥¥ë¥¹°ß´â¤ÎÊ¢Ëìž°Ü¡¡¡¦¡¦¡¦Ê¢Ë잰ܤμ£ÎÅ¡¡ÈóÀÚ½ü¤ÈÀÚ½ü¤ÎÎ×¾²ÉÂÍý³ØÅªÆÃħ¤È¼£ÎÅÀ®ÀÓ¡¡Ê¢ËìÇżðÍÛÀ¤ÈÇżð±¢À¤òºÙ˦À¡¦¡¦ ¢¡ | ¥¹¥¥ë¥¹ ¾ |
 |
 | 4·¿°ß´âº¬¼£½Ñ¸å¤Î¥ê¥ó¥ÑÀáºÆÈ¯¤ËTS-1¤¬Í¸ú¤Ç¤¢¤Ã¤¿1Îã ¢¡ | °ß´â ¾ |
 |
 | 5'-Deoxy-5-Fluorouridine(5'-DFUR),Medroxyprogesterone Acetate(MPA),Cyclophosphamide(CPA)Ê»ÍÑÎÅË¡(DMpCÎÅË¡)¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÆý´â¤Î2Îã ¢¡ | £··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾ |
 |
 | 5'-DFUR + CPA + THPÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿PaclitaxelÄñ¹³ÀÆý´âÇÙž°Ü¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | 5'-DFUR(5'-Deoxy-5-Fluorouridine)+MPA(Medroxyprogesterone Acetate)Ê»ÍÑÎÅË¡¤ÇĹ´ü´²²ò¤òÆÀ¤Æ¤¤¤ëºÆÈ¯Æý´â¤Î1¾ÉÎã ¢¡ | °ß´â ¾ |
 |
 | 5'-DFUR,CisplatinÎÅË¡,¼ê½ÑÎÅË¡¤Ë¤è¤ê½Ñ¸å10ǯ°Ê¾å̵ºÆÈ¯À¸Â¸¤òÆÀ¤Æ¤¤¤ë°ß´â¿ȯ´Îž°Ü¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | 5'-DFUR¡¦MPAÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÀÔÄÇ¡¦ÀÔ¿ñž°Ü¤òȼ¤¦¿Ê¹ÔÆý´â ¢¡ | Æý´â ¾ |
 |
 | 5'-DFUR¡ÜMMCÊ»ÍÑÎÅË¡¤Ë¤è¤ê´°Á´´²²ò¤·¤¿ÂçIJ´â´Îž°Ü¤Î1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | 5'-DFUR¤¬Ãø¸ú¤·¤¿ÂçIJ´â´Îž°Ü¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | 5'-DFUR¤Ë¤è¤ê¾Ã¼º¤·¤¿PyNPaseÍÛÀÂçIJ´â¤Î¿ȯÀ´Îž°Ü¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | 5'-DFURñºÞÅêÍ¿¤¬Ãø¸ú¤ò¼¨¤·¤¿¿Ê¹ÔÆý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | 5'-DFURÄãÍÑÎÌÅêÍ¿¤È¥Û¥ë¥â¥óÎÅË¡¤ÎÊ»ÍѤ¬Í¸ú¤Ç¤¢¤Ã¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | 5-Fluorouraci1/l-LeucovorinưÃíÎÅË¡¤Ë¤è¤êĹ´ü´Ö¿Ê¹Ô¤¬À©¸æ¤µ¤ì¤Æ¤¤¤ëľIJ´â¸¶È¯´Îž°Ü¤Î1¾ÉÎã ¢¡ | ·ëIJ´â ¾ |
 |
 | 5-Fluorouracil/l-Leucovorin¤Ë¤è¤ëÁ´¿È²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¿Ê¹ÔÂçIJ´â¤Î1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | 5-Fluorouracil/l-LeucovorinÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÂçIJ´â´Îž°Ü¤Î2Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | 5-Fluorouracil´ÎưÃíÎÅË¡Ãæ¤Ë¶¹¿´¾Éȯºî¤òÍ褷¤¿Å¾°ÜÀ´Î´â¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | 5-FU+Interferon-¦ÁÊ»ÍÑÎÅË¡¤Ë¤ª¤±¤ë5-FUÂå¼Õ´ØÏ¢¹ÚÁdzèÀ¤Î¸¡Æ¤¡¾¥Ì¡¼¥É¥Þ¥¦¥¹²Ä°Ü¿¢À¥Ò¥È´ÎºÙ˦´â³ô¤Ë¤ª¤±¤ë¸¡Æ¤ ¢¡ | ´Î¡´â ¾ |
 |
 | 5-FU,Adriamycin,CDDP(FAP)¤Ë¤è¤ë3ºÞÊ»ÍÑ´ÎÆ°Ãí²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÃÀ´ÉºÙ˦´â¤Î2Îã ¢¡ | ÃÀÆ»´â ¾ |
 |
 | 5-FU,CDDP,Adriamycin¤Î3ºÞÊ»ÍÑÆ°Ãí²½³ØÎÅË¡¤Ë¤è¤êCR¤¬ÆÀ¤é¤ì¤¿¿Ê¹Ô´ÎºÙ˦´â(Vp4,Vv3,IM3)¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | 5-FU/CPT-11ÅêÍ¿¤Ë¤è¤êCR¤¬ÆÀ¤é¤ì¤¿ÂçIJ´â½Ñ¸å¤Î´Îž°Ü¤ª¤è¤ÓÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤÎ1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | 5-FU/LV´Îư̮ÃíÆþ²½³ØÎÅË¡¤Ë¤è¤ëž°ÜÀ´Î´â¼£ÎžÉÎã¤Î¸¡Æ¤ ¢¡ | ·ëIJ´â ¾ |
 |
 | 5-FU/MMC/CDDP»°ºÞÊ»ÍÑÎÅË¡¸å¤ËTS-1ÎÅË¡¤ò¹Ô¤¤Í¸ú¤Ç¤¢¤Ã¤¿ºÆÈ¯°ß´â¤Î3Îã ¢¡ | °ß´â ¾ |
 |
 | 5-FU¡¤CDDP¡¤Adriamycin(FAP)¤Ë¤è¤ë´ÎưÃí²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¿Ê¹Ô´ÎºÙ˦´â¤Î2Îã ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | 5-FU¡¦¥í¥¤¥³¥Ü¥ê¥óÎÅË¡¤¬ÁÕ¸ú¤·¤¿½Ä³Ö¥ê¥ó¥ÑÀᡦ´Îž°Ü¤òͤ¹¤ëľIJ´â¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | 5-FU¤ò´Þ¤àÊ»ÍѲ½³ØÎÅË¡¤Ë̵¸ú¤È¤Ê¤Ã¤¿ºÆÈ¯·ëIJ¡¦Ä¾Ä²´â¾ÉÎã¤ËÂФ¹¤ëSecond-Line Chemotherapy¤È¤·¤Æ¤ÎBi-Weekly CPT-11+CDDPÊ»ÍÑÎÅË¡¤Î¸¡Æ¤ ¢¡ | ·ëIJ´â ¾ |
 |
 | 5-FU´ÎưÃíÎÅË¡¤Ë¤ÆÈÆ·ìµå¸º¾¯,ARDS¤òÍ褷¤¿1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | 5-FU·Ï¹³´âºÞÄñ¹³À¤Î¿Ê¹Ô¡¦ºÆÈ¯°ß´â¤ËÂФ¹¤ëWeekly PaclitaxelÎÅË¡¤ÎFeasibility Study ¢¡ | °ß´â ¾ |
 |
 | 5-FUưÃí¤ÈIFNÅêÍ¿¤Ë¤Æ³°Íè²ÃÎÅÃæ¤Î¤ÓÌ¡·¿´Î´â¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | 50ºÐ°Ê¾å¤Î·ì±Õ¼À´µ¤ËÂФ¹¤ëƱ¼ï¤·ì´´ºÙ˦°Ü¿¢ ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | 5cmÂç¤Î¸åÊ¢ËìÊ¿³ê¶ÚÆù¼ð¤Î1Îã¡¡¡¦¡¦¡¦¾ÉÎã
57ºÐ,½÷À
¹Í»¡¡¡¡¦¡¦ ¢¡ | £³·îÂ裴½µ¡§£²£¶Æü(ÅÚ¡Ë Â¾ |
 |
 | 5¡-DFUR,CimetidineÊ»ÍÑÎÅË¡¤Ë¤è¤êĹ´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿ÂçIJ´âƱ»þÀ¿ȯÇÙž°Ü¤Î1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | 60Gy̤Ëþ¤ÎÊü¼ÍÀþ¼£ÎŤˤÆCR¤¬ÆÀ¤é¤ì¤¿È󾮺Ù˦ÀÇÙ´â¤Î²¹Ç®ÎÅË¡¤Î9¾ÉÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | 65ºÐ°Ê¾å¤ÎC·¿ËýÀ´Î¼À´µ¤Îͽ¸å¡¦´Î´âȯ´âΨ ¢¡ | ´Î±ê ¾ |
 |
 | 6cmÂç¤Îº¿¹ü¾åãÝ¥ê¥ó¥ÑÀឰܤȸ¶È¯Á㤬²¹Ç®Ê»ÍÑÊü¼ÍÀþ¼£ÎŤÇÀ©¸æ¤Ç¤¤¿¿Ê¹Ô¿©Æ»´â¤Î°ìÎã ¢¡ | ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾ |
 |
 | 6ǯ°Ê¾å¤ÎĹ´üÀ¸Â¸¤òÆÀ¤Æ¤¤¤ëÃøÌÀ¤Ê´Îž°Ü¤òȼ¤¦½éȯ°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | 7 ǯ¤Î·Ð²á´Ñ»¡¤Î¤Î¤Á¾Ã²½´É½Ð·ì¤Çȯ¾É¤·¤¿½½Æó»ØÄ²¸¶È¯ GIST ¤Î 1 Îã¡¡ ¢¡ | GIST ¾ |
 |
 | 76ºÐ°Ê¾å¤Î¹âÎð¼Ô¾®ºÙ˦ÇÙ´â¤ËÂФ¹¤ëCarboplatin,EtoposideÊ»ÍÑÎÅË¡ ¢¡ | ¾®ºÙ˦´â ¾ |
 |
 | 80ºÐ°Ê¾å¹âÎð¼ÔÇÙ´â´µ¼Ô¤Î¼£ÎÅÀ®ÀÓ¡¡¡¦¡¦¡¦¹âÎð¼ÔÇÙ´â¤Ë¤ª¤±¤ë¼£ÎŤΰÌÃÖÉÕ¤±¤ò¹Ô¤¦ÌÜŪ¤Ç¡¢»Ü¹Ô¤·¤¿¼£ÎÅË¡¤Èͽ¸å¤Ë½ÅÅÀ¤ò¤ª¤¤¤ÆÎ×¾²Åª¸¡¡¦¡¦ ¢¡ | ÇÙ´â ¾ |
 |
 | A Breast Cancer Patient with Myelodysplastic Syndrome Postoperatively Treated by Radiation and Tamoxifen Administration ¡ÝA Case Report | 33-06 |
 |
 | A Pilot Study of Weekly Paclitaxel Administration for Patients with Relapsed Cervical Cancer after Heavy Medication ¢¡ | £··îÂ裴½µ¡§£²£´Æü¡ÊÆü¡Ë ¾ |
 |
 | A Translation of the Multidimensional Affect and Pain Survey (MAPS) from English to Japanese | 30-05 |
 |
 | ABCF2ÃÁÇòȯ¸½¤Ï,ÍñÁãÌÀºÙ˦Á£´â¤Î¹³´âºÞ´¶¼õÀ¤ª¤è¤Óͽ¸å¤òͽ¬¤·¤¦¤ë¤«?¡¡¡Ý¥ª¡¼¥À¡¼¥á¥¤¥É°åÎŤòÌܻؤ·¤Æ¡Ý ¢¡ | 9·îÂ裱½µ¡Ê1Æü¡Ë ¾ |
 |
 | ABC¥È¥é¥ó¥¹¥Ý¡¼¥¿¡¼¤ÈÌôºÞ±þÅúÀ¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | adenoid cystic carcinoma¤ËÂФ·¤Æconcurrent chemoradiation therapy¤¬Ãø¸ú¤·¤¿°ìÎã ¢¡ | »ÒµÜ·Û´â ¾ |
 |
 | Adjuvant¡¡Chemotherapy¤ò¤á¤°¤ëControversy | 31-02 |
 |
 | ADM,CDDP,ETP,5-FUÊ»ÍÑÎÅË¡¤Ë¤Æ´°Á´´²²ò¤òÆÀ¤é¤ì¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | AFP¤ª¤è¤ÓPIVKA-II»ºÀ¸°ß´â¤Î1Îã ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | Aggressive B-cell Non-Hodgkin's Lymphoma¤ËÂФ¹¤ë¼«²È¤·ì´´ºÙ˦°Ü¿¢ ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | AIDS¤Ë¹çÊ»¤¹¤ë°À¥ê¥ó¥Ñ¼ð¡¡¡¦¡¦¡¦Ù¨Åí°À¥ê¥ó¥Ñ¼ð¡¦¡¦ ¢¡ | ƬðôÉô ¾ |
 |
 | Amrubicin¤Î³Ö½µÅêÍ¿¤Ë¤è¤ê¼ðáç¥Þ¡¼¥«¡¼¤Î²þÁ±¤¬¤ß¤é¤ì¤¿¾®ºÙ˦ÇÙ´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | AnastrozoleÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÇÙ¡¦¶»Ë잰ܤòȼ¤¦¿Ê¹ÔÆý´â¤Î1Îã ¢¡ | Æý´â ¾ |
 |
 | Angiotensin II blocker¤òÍѤ¤¤¿ºÆÇ³ÀÁ°Î©Á£´â¼£ÎŤδðÁäÈÎ×¾² ¢¡ | Á°Î©Á£´â ¾ |
 |
 | Angiotensin-II(AT-II)Ê»ÍÑPharmacokinetics Modulating Chemotherapy(PMC)¾º°µÊÑˡưÃí²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯´Îž°Ü¥ê¥ó¥ÑÀឰܿʹ԰ߴâ¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | Anthracycline¤ª¤è¤ÓTaxaneÂÑÀºÆÈ¯Æý´â¤ËÂФ¹¤ëCapecitabine¤Î»ÈÍѷи³ ¢¡ | 2·î ¾ |
 |
 | Ara-CÂçÎÌÎÅË¡¤ò´Þ¤à¶¯²½ÎÅË¡¸å,IJ´ÉÀü¹¦,¾®Ä²·ìÀò¾É¤ò¤¤¿¤·¤¿µÞÀ¹ü¿ñÀÇò·ìɤÎ1Îã ¢¡ | Çò·ìÉ ¾ |
 |
 | Asian Trends in Prostate Cancer Hormone Therapy ¢¡ | Á°Î©Á£´â ¾ |
 |
 | ATL¤Îʬ»ÒÉÂÍý¡¡¡¦¡¦¡¦¿·¤·¤¤¥ê¥ó¥Ñ¼ð¤ÎʬÎप¤è¤Ó¼£ÎÅ ¡¡
ATLºÙ˦¤Ë¤Ä¤¤¤Æ¡¢¸½ºßÌÀ¤é¤«¤Ë¤Ê¤Ã¤Æ¤¤¤ë¾ðÊ󡦡¦ ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | Attenuated familial adenomatous polyposis(AFAP)¤òµ¿¤Ã¤¿°Û»þÀ¿ȯÂçIJ´â¤Î1Îã ¢¡ | £´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Aurora¥¥Ê¡¼¥¼¤È¤¬¤ó¡¡¡¦¡¦¡¦Aurora¥¥Ê¡¼¥¼¥Õ¥¡¥ß¥ê¡¼¤Îµ¡Ç½
Aurora-A
Aurora-B
A¡¦¡¦ ¢¡ | ¥²¥Î¥à ¾ |
 |
 | A·²ÍÏÏ¢¶Ý´¶À÷¤ò¹çÊ»¤·¤¿ÈØÉô¶ÚÆùÆâ³¤Ìʾõ·ì´É¼ð ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | Barrett¿©Æ»´â¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | ¿©Æ»´â ¾ |
 |
 | Barrett¿©Æ»Á£´â¡¡¡¦¡¦¡¦Èæ³ÓŪ¤Þ¤ì¤Ê¼ðáç¤Î¿ÇÃǤȼ£ÎŶ¡¦¡¦ ¢¡ | ¿©Æ»´â ¾ |
 |
 | Basedow ɤòÄ褷¤¿¶¶ËÜɤËÀ¸¤¸¤¿¹Ã¾õÁ£ MALT ¥ê¥ó¥Ñ¼ð¤Î 1 Îã¡¡ ¢¡ | £²·îÂ裲½µ¡§£±£±Æü¡Ê¶â¡Ë ¾ |
 |
 | BisphosphonateÎÅË¡¤¬¹üž°Ü¤Ë͸ú¤Ç¤¢¤Ã¤¿Æý´â¿¡´ïž°ÜºÆÈ¯¤Î1¾ÉÎã ¢¡ | ¹üž°Ü ¾ |
 |
 | BisphosphonateÎÅË¡¤Ë¤è¤Ã¤Æ¹üž°Ü¤ÎÄˤߤ¬·Ú¸º¤·¤¿3¾ÉÎã ¢¡ | ¹üž°Ü ¾ |
 |
 | ¢¡3922 | °ß´â ¾ |
 |
 | BNP¤¬Â¿ºÞÊ»ÍѲ½³ØÎÅË¡¤Ë¤ª¤±¤ë¿´¶ÚÆÇÀ¤Îɾ²Á¤ËÍÍѤǤ¢¤Ã¤¿2ÍÄ»ùÎã ¢¡ | £¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾ |
 |
 | ¢¡3738 | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | B·¿´Î¹ÅÊѤ˹çÊ»¤·¤¿Aeromonas hydrophila ÇÔ·ì¾É¤Î1˶¸¡Îã ¢¡ | ´Î¡´â ¾ |
 |
 | C ·¿´Î±ê¤Ë¤ª¤±¤ë½É¼çÌȱ֤βòÀϤȤ½¤Î¿ÊÊâ ¢¡ | ´Î¡´â ¾ |
 |
 | c-kitÍÛÀÊ¿³ê¶Ú¡¦¿À·Ðº®¹ç·¿¾®Ä²GIST¤Î1Îã ¢¡ | GIST ¾ |
 |
 | cag PAI¤È°ßȯ´â¡¡¡¦¡¦¡¦CagA
cag PAI¡¡
p53¡¡¡¦¡¦ ¢¡ | ¥Ô¥í¥ê¶Ý ¾ |
 |
 | Cancer Prevention¡¡¡¦¡¦¡¦Âè12²óncology forum¤Ç¤Î¸¡Æ¤ÆâÍÆ¤ò¤Þ¤È¤á¤¿¡£¡¡¤¬¤óͽËɤοÊŸ¤Èº£¸å¤ÎÀïά¤Ë¡¦¡¦ ¢¡ | 2·îÂè4½µ ¾ |
 |
 | Capecitabine-TrastuzumabÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿PaclitaxelÉÔ±þÀºÆÈ¯Æý´â¤Î1¾ÉÎã ¢¡ | 5·î ¾ |
 |
 | Capecitabine¤¬Ãø¸ú¤·¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ | 2·î ¾ |
 |
 | Capecitabine¤ÈDoxifluridine¤ÎÌôʪưÂÖ¤ÎÈæ³Ó¸¡Æ¤ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Carboplatin ¡Ý¤³¤ì¤«¤é¤ÎÆý´â¼£ÎÅÌô ¢¡ | 8·îÂ裴½µ¡¡£²£¶Æü ¾ |
 |
 | Carboplatin+Docetaxel¤Ë¤è¤ë²½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¹âÎð¼ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | Carboplatin+EtoposideÊ»ÍѲ½³ØÎÅË¡¤ª¤è¤ÓÊü¼ÍÀþÎÅˡƱ»þÊ»ÍѤ¬Í¸ú¤Ç¤¢¤Ã¤¿¶»Á£´â¤Î1Îã ¢¡ | ¶»Éô ¾ |
 |
 | Carboplatin+Weekly Paclitaxe1Ê»ÍÑÎÅË¡¤Ë¤Æ°Àγ»¶ÉÛ·¿ÇÙž°Ü¤¬´°Á´¾Ã¼º¤·¤¿ÇÙÁ£´â¤Î1Îã ¢¡ | ÇÙ´â ¾ |
 |
 | Carboplatin¤ÈDocetaxel¤Ë¤è¤ëÇÙ´â²½³ØÎÅË¡»þ¤Î·ì¾®Èĸº¾¯´ËϺîÍѤ˴ؤ¹¤ë¸¡Æ¤ ¢¡ | ÇÙ´â ¾ |
 |
 | Carboplatin¤ÈPaclitaxel¤ÎËè½µÅêÍ¿¤¬Ãø¸ú¤·¤¿µ¤´É»Ù٨ʿ¾åÈé´â¤Î1Îã ¢¡ | ٨ʿ¾åÈé´â ¾ |
 |
 | Carmofur(HCFU)¤òÍѤ¤¤¿ÂçIJ´â¤Î½ÑÁ°²½³ØÎÅË¡ ¢¡ | ÂçIJ´â ¾ |
 |
 | CD-DSTË¡¤òÍѤ¤¤¿´ÎºÙ˦´â¤ËÂФ¹¤ë¹³´âºÞ´¶¼õÀ»î¸³ ¢¡ | ´Î¡´â ¾ |
 |
 | CDDP+5-FU+ADMÊ»ÍѲ½³ØÊü¼ÍÀþÎÅË¡¤Ë¤ÆCR¤¬ÆÀ¤é¤ì¤¿Ê¢Éô¥ê¥ó¥ÑÀáž°ÜÍÛÀ¤Î¿ȯ¿Ê¹Ô¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | CDDP+5-FU¤Î´Ö·çŪ´ÎưÃí¤¬´Î¸¶È¯Á㤪¤è¤Ó¿ȯÇÙž°ÜÁã¤ËÁÕ¸ú¤·¤¿´ÎºÙ˦´â¤Î1Îã ¢¡ | ´Î¡´â ¾ |
 |
 | CDDP+5-FUÌë´ÖÅêÍ¿¤Ë¤è¤ëChronomodulationÎÅË¡¤ò»Ü¹Ô¤·¤¿¿Ê¹Ô°ß´â¤Î3Îã ¢¡ | °ß´â ¾ |
 |
 | CDDP+CPT-11ÎÅË¡¤ª¤è¤ÓGemcitabineÎÅË¡¤Ë¤ÆÄ¹´üÀ¸Â¸¤¬²Äǽ¤È¤Ê¤Ã¤¿ÃÀǹ´âºÆÈ¯¤Î1Îã ¢¡ | £²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | CDDP,CPT-11,5-FU¤Ë¤è¤ë´Îư̮²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Î³°Å¾°Ü¤òͤ¹¤ëÂçIJ´â´Îž°Ü¤Î1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | CDDP,TS-1Ê»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤è¤êÁÈ¿¥³ØÅª¤Ë¼ðáçºÙ˦¤Î¾Ã¼º¤¬Ç§¤á¤é¤ì¤¿¿Ê¹Ô¾å³Ü´â¤Î1Îã ¢¡ | ¾å³Ü´â ¾ |
 |
 | CDDP,VDS,MMCÊ»ÍѲ½³ØÎÅË¡¡¦¶»ÉôÊü¼ÍÀþ¼£ÎŸå¤Ë¼ê½Ñ¤¬¹Ô¤ï¤ì¤¿¶É½ê¿ÊŸ·¿È󾮺Ù˦ÇÙ´â¤Î½Ñ¸åÇÙÆÇÀ¤Ë´Ø¤¹¤ë¸¡Æ¤ ¢¡ | È󾮺Ù˦´â ¾ |
 |
 | CDDP,VinorelbineÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿´Îž°Ü¤òȼ¤¦ÇÙÂçºÙ˦´â¤Î1Îã ¢¡ | ÂçºÙ˦´â ¾ |
 |
 | CDDP¤Ë¤è¤ëÇÙ´â²½³ØÎÅË¡¤Ë¤ª¤±¤ëOndansetron Hydrochloride¤È¥¹¥Æ¥í¥¤¥ÉºÞ¤ÎÊ»ÍѤ˴ؤ¹¤ë¸¡Æ¤ ¢¡ | ÇÙ´â ¾ |
 |
 | CDDPÊ¢¹ÐÆâÅêÍ¿¡ÜTS-1Ê»ÍÑÎÅË¡¤Ë¤è¤ê´âÀÊ¢¿å¤¬¾Ã¼º¤·¤¿¿Ê¹ÔÀ°ß´â¤Î1Îã | 39-02 |
 |
 | Cdx2¤È°ß´â ž¼Ì°ø»Ò¤È¾Ã²½´É´â¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ | £¸·î£±Æü ¾ |
 |
 | CEA¤Î¿ä°Ü¤«¤é¤ß¤¿ÂçIJ´â´Îž°Ü(H3)¤ËÂФ¹¤ëDegradable Starch Microsphere(DSM),Adriamycin(ADM),Mitomycin C(MMC)´ÎưÃíÎÅË¡¤Î¸ú²ÌȽÄê ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | CEF Followed Docetaxel¤Ë¤è¤ëÆý´â½ÑÁ°²½³ØÎÅË¡¤Î°ÂÁ´À,͸úÀ¤Ë´Ø¤¹¤ë¸¡Æ¤ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Changes in Hepatic Parenchymal Ultrasound Images in Tamoxifen Medication Patients ¢¡ | Êü¼ÍÀþ´ØÏ¢ ¾ |
 |
 | Cimetidine¤Ë¤è¤ëSialyl Lewis(sLe)¹³¸¶¹âȯ¸½´â¤Î·ì´ÉÆâÈ館¤ÎÀÜÃåÍÞÀ© ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Cis-Platinum½ùÊüÀInjectable Drug Carrier ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Cisplatin and Gemcitabine in Patients with Metastatic Cervical Cancer | 31-07 |
 |
 | Cisplatin(CDDP)+Paclitaxel(PTX)Ê¢¹ÐÆâÅêÍ¿¤Ë¤è¤êÊ¢¿å¤¬·Ú²÷¤·¤¿°ÀÊ¢ËìÃæÈé¼ð¤Î1Îã ¢¡ | °ÀÃæÈé¼ð ¾ |
 |
 | Cisplatin+DocetaxelÊ»ÍѲ½³ØÎÅË¡¤Ë¤è¤ê´°Á´´²²ò¤¬ÆÀ¤é¤ì¤¿¶É½ê¿Ê¹Ô´üÇÙ٨ʿ¾åÈé´â¤Î1Îã ¢¡ | ٨ʿ¾åÈé´â ¾ |
 |
 | Cisplatin+GemcitabineÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¸ý¹Ð´âºÆÈ¯Á´¿Èž°Ü¤Î1¾ÉÎã ¢¡ | ¸ý¹Ð´â ¾ |
 |
 | Cisplatinum,5-Fluorouracil,Levofolinate Calcium´Îư̮ÃíÆþ,ÂçÆ°Ì®ÃíÆþÊ»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿°ß´â¿ȯ´Îž°Ü¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | Cisplatin¤Î¿´Ç¹ÆâÃíÆþ¤¬ÁÕ¸ú¤·¤¿Æý´â¿´Ç¹Å¾°Ü¤Î1Îã ¢¡ | 2·î ¾ |
 |
 | Cisplatin´ÎưÃíÎÅË¡¤ÈTS-1·Ð¸ýÅêÍ¿¤¬ÁÕ¸ú¤·¤¿ç¹Á£Ë¼ºÙ˦´â´Îž°Ü¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | CisplatinͶȯ°¿´¡¦ÓÒÅǤËÂФ¹¤ëRamosetron¤ÈDexamethasoneÊ»ÍÑÎÅË¡¤ÎÎ×¾²¸ú²Ì-Dexamethasone¤ÎÍÑÎ̳Îǧ»î¸³- ¢¡ | ¸ý¹Ð´â ¾ |
 |
 | Cladribine¡¡¡¦¡¦¡¦ÂèµÁê»î¸³¡¡³¤³°¤Ç¤ÎÂè¶Áê»î¸³¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | Cladribine¤ÎÅêÍ¿¤Ë¤è¤ê´²²òƳÆþ¤ª¤è¤Ó¹ü¿ñÀþ°Ý²½¤ÈÈ鿾¤Î²þÁ±¤¬ÆÀ¤é¤ì¤¿Hairy Cell Leukemia ¢¡ | ¤½¤Î¾¤Î´â ¾ |
 |
 | Clinical Benefit¤«¤é¤ß¤¿¿Ê¹Ôç¹´â¤ËÂФ¹¤ëGemcitabine¤ÎÍÍÑÀ ¢¡ | ç¹Â¡´â ¾ |
 |
 | CMF¤Ë¤è¤ëThird-Line Chemotherapy¤¬Ãø¸ú¤·¤¿Æý¤¬¤ó½Ñ¸åÇÙž°Ü¤Î1Îã ¢¡ | ¶»Éô ¾ |
 |
 | Combination of Vinorelbine+Doxorubicin in Advanced Breast Cancer ¢¡ | Æý´â ¾ |
 |
 | Cost-effectiveness of Letrozole versus Tamoxifen as First-line Hormonal Therapy in Treating Postmenopausal Women with Advanced Breast Cancer in Japan ¢¡ | £··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾ |
 |
 | Covered Type¿©Æ»Stent¤Ë¤è¤êÎɹ¥¤ÊQOL¤¬ÆÀ¤é¤ì¤¿¿©Æ»µ¤´Éáñ¤òͤ¹¤ë¶»Éô¾åÉô¿©Æ»´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | COX-2 Á˳²Ìô¤Î¿ÌÌÀ¤Èº£¸å¤Îư¸þ¡¡¡¦¡¦¡¦COX-1 COX-2 Èæ³Ó¡¡
¹üÂå¼Õ¡¡
¥¢¥Ý¥È¡¼¥·¥¹¡¡Èó¥¹¥Æ¥í¥¤¥É¹³±ê¾ÉÌô NSA¡¦¡¦ ¢¡ | 31-1 ¾ |
 |
 | COX-2¤È´â¼£ÎŸ¦µæ¡¡¡¦¡¦¡¦COX¤ÎºîÍÑ¡¡
´â¤Ë¤ª¤±¤ëCOX-2¤Îȯ¸½¡¡
COX-2Á˳²ºÞ¤Ë¤è¤ë´â¼£ÎÅ¡¡
¡¡È¯¡¦¡¦ ¢¡ | ²½³ØÎÅË¡ ¾ |
 |
 | CPT-11+CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿°ß´âÊ¢ËìÇÅ¼ïºÆÈ¯¤Î1Îã ¢¡ | £··îÂ裵½µ¡§£³£±Æü¡ÊÆü¡Ë ¾ |
 |
 | CPT-11+TS-1Ê»ÍѲ½³ØÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿´Î¡¦ÇÙ¡¦¥ê¥ó¥ÑÀឰܺÆÈ¯·ëIJ´â¤Î1Îã | 33-06 |
 |
 | CPT-11+TS-1Ê»ÍѲ½³ØÎÅË¡¤Ë¤è¤êÊ¢ËìÇż郎¾Ã¼º¤·CR¤È¤Ê¤Ã¤¿1Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | CPT-11+UFT-EÊ»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿1¾ÉÎã ¢¡ | ·ëIJ´â ¾ |
 |
 | CPT-11/5-FU/l-LeucovorinÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔÂçIJ´â4¾ÉÎã ¢¡ | ÂçIJ´â ¾ |
 |
 | CPT-11/CDDPÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Îž°Ü¤òȼ¤¦AFP»ºÀ¸°ß´â¤Î1Îã ¢¡ | °ß´â ¾ |
 |
 | CPT-11¤¬Í¸ú¤Ç¤¢¤Ã¤¿¿©Æ»¾®ºÙ˦´â¤Î1Îã ¢¡ | ¿©Æ»´â ¾ |
 |
 | CPT-11¤ò´Þ¤à¿ºÞÊ»ÍѲ½³ØÎÅË¡ :¿Ê¹Ô°ß´â¤ËÂФ¹¤ë¿ºÞÊ»ÍѲ½³ØÎÅË¡ ¢¡ | °ß´â ¾ |
 |
 | CPT-11¥Ù¡¼¥¹¤Î²½³ØÎÅË¡¤Ë¤è¤ê3ǯ¤Ë¤ï¤¿¤êĹ´üÀ¸Â¸¤¬ÆÀ¤é¤ì¤¿ÂçIJ´â¤Î1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | CPT-11´ÎưÃí+UFTÆâÉþ¤¬Í¸ú¤Ç¤¢¤Ã¤¿Ä¾Ä²´â´Îž°Ü¤Î2Îã ¢¡ | ·ëIJ´â ¾ |
 |
 | CPT-11Äñ¹³ÀÀÚ½üÉÔǽ¿Ê¹ÔÂçIJ´â¤ËÂФ·Oxaliplatin(L-OHP)/5-FU/l-LV¤òÍѤ¤¤¿Chronotherapy¤¬Í¸ú¤Ç¤¢¤Ã¤¿1Îã ¢¡ | ÂçIJ´â ¾ |
 |
 | CPT-11Ê»ÍÑLow-Dose CDDP+5-FUÎÅË¡¤¬ÁÕ¸ú¤·¤¿´Îž°Ü,ÂçÆ°Ì®¼þ°Ï¥ê¥ó¥ÑÀឰܤòȼ¤¦¿Ê¹Ô°ß´â¤Î1Îã ¢¡ | ž°ÜÀ´Î¡´â ¾ |
 |
 | CrohnɤÈIJ´â¡¡¡Ý±ê¾ÉÀIJ¼À´µ¤Èȯ´â¡¡¡¦¡¦¡¦CrohnÉ¡¡ÂçIJ´âȯÀ¸¤Îµ¡½ø¡¡
£É£Â£Ä¤Ë¹çÊ»¤¹¤ëÂçIJ´â¡Ê£Ã£Á£Ã¡Ë¤ÎÉÑÅÙ¡¦Î×¾²Áü¡¡
¡¦¡¦ ¢¡ | £±£°·î£±Æü£Õ£Ð ¾ |
 |
 | CT¡¤ERCP¡¡¡¦¡¦¡¦ç¹´â¿ÇÎŤθ½¾õ¤ÈÁá´üȯ¸«¤Î¹©Éס¿¥Ð¥ë¡¼¥ó¥«¥Æ¡¼¥Æ¥ë繴ɤ±Æ¡¾°µÇ÷»£±ÆË¡¡¿ERP ¤Î¼êµ»¤ò¡¦¡¦ | 76 |
 |
 | CT¤Ë¤è¤ë°ß´âÊ¢Ëìž°Ü¿ÇÃǤÎÍÍÑÀ¡¡¡¦¡¦¡¦½ÑÁ°Ê¢ÉôCT¸¡ºº¤ÎÎ×¾²Åª°ÕµÁ¡¦¡¦ ¢¡ | °ß´â ¾ |
 |
 | CT¤Ë¤è¤ëç¹´â¤Î½ÑÁ°¥¹¥Æ¡¼¥¸¥ó¥°¡Ý¸åÊ¢Ëì¿»½á¤Ê¤é¤Ó¤Ë¥ê¥ó¥ÑÀáž°Ü¿ÇÃÇ¡¼ ¢¡ | ç¹Â¡´â ¾ |
 |
 | CTÆ©»ë¤òÍѤ¤¤¿ÇÙ°À¼ðáç¤ËÂФ¹¤ë·ÐÈéŪÅà·ë¼£ÎÅ¤Î¼ÂºÝ ¢¡ | 29-3 ¾ |
 |
 | Cyclophosphamide,Vincristine,Dacarbazine¤Î3ºÞÊ»ÍÑÎÅË¡¤¬Í¸ú¤Ç¤¢¤Ã¤¿°À³ì¿§ºÙ˦¼ð¤Î1Îã ¢¡ | ÈéÉæ ¾ |
 |
 | C·¿´Î±ê¤ËȯÀ¸¤·¤¿À®¿Í´Î²ê¼ð¤Î1ÀÚ½üÎã¡¡¡¦¡¦¡¦¡¦¡¦ | 39-01 |
 |
 | C·¿´Î±ê¥¦¥¤¥ë¥¹¤Î±¡Æâ´¶À÷¡¡¡¦¡¦¡¦°åÎŽ¾»ö¼Ô¤«¤é´µ¼Ô¤Ø¤Î´¶À÷¡¡
´µ¼Ô¤«¤é°åÎŽ¾»ö¼Ô¤Ø¤Î´¶À÷¡¡
´µ¼Ô¤«¤é´µ¼Ô¤Ø¤Î´¶À÷¡¡¡¦¡¦ ¢¡ | ´Î±ê ¾ |
 |
 | C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡
HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡
HCV¤Î¥ï¡¦¡¦ ¢¡ | ´Î±ê ¾ |
 |
 | C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡
HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡
HCV¤Î¥ï¡¦¡¦ ¢¡ | ´Î±ê ¾ |
 |
 | C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡
HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡
HCV¤Î¥ï¡¦¡¦ ¢¡ | 59-07 ¾ |
 |
 | C·¿´Î±ê¥ï¥¯¥Á¥ó³«È¯¸¦µæ¤Î¸½¾õ¡¡¡¦¡¦¡¦HCV°äÅÁ»Ò¹½Â¤¤È¥¦¥£¥ë¥¹ÃÁÇò¼Á¡¡
HCV¤Î¥ï¥¯¥Á¥ó³«È¯¤Ë¤ª¤±¤ëÌäÂêÅÀ¡¡
HCV¤Î¥ï¡¦¡¦ ¢¡ | 59-07 ¾ |
 |
 | C·¿´Î±ê´µ¼Ô¤ËȯÀ¸¤·¤¿´Î°À¥ê¥ó¥Ñ¼ð¤Î1Î㤪¤è¤ÓËÜË®Êó¹ðÎã¤Îʸ¸¥Åª¹Í»¡ ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | C·¿ËýÀ´Î±ê¤Ë¤ª¤±¤ë¾åÊ¢Éô²Ã²¹¸ú²Ì¤Î¸¡Æ¤(Âè1Êó) | 22²ó¡¡Âç²ñ |
 |
 | C·¿ËýÀ´Î±ê¤Ë¤Æ·Ð²á´Ñ»¡Ãæ¤Ë²«áÕ¤ò·Àµ¡¤Ëȯ¸«¤µ¤ì¤¿Ê¢Éô¸¶È¯Èó¥Û¥¸¥¥ó¥ê¥ó¥Ñ¼ð¤Î1Îã ¢¡ | °À¥ê¥ó¥Ñ¼ð ¾ |
 |
 | C·¿ËýÀ´Î±ê¤Ë¹çÊ»¤·¤¿´ÎÆâÃÀ´ÉÁ£¼ð¤Î1Î㡽²èÁü½ê¸«¤òÃæ¿´¤Ë¡½ ¢¡ | ´ÎÆâÃÀ´É´â ¾ |
 |
 | C·¿ËýÀ´Î±ê¤ËÂФ¹¤ë´Îȯ´âÍÞÀ©¤òÌÜŪ¤È¤·¤¿IFN¼£ÎÅ ¢¡ | ´Î±ê ¾ |
 |
 | C·¿ËýÀ´Î±ê¤Î²¹Ç®ÎÅË¡¤Ë¤è¤ë´ÎÁÈ¿¥Æâ°äÅÁ»Òȯ¸½¤ÎÊѲ½ ¢¡ | 21-Supplement ¶ ¾ |
 |